It has been shown that simultaneous inhibition of the insulin receptors, IGF1 and MET receptors as well as the epidermal growth factor receptors (EGFR) enhances efficacy of EGFR-inhibitors in colon cancer xenografts (106). Here, INSR is linked to malignant colon neoplasm.